References
- Prozialeck WC, Jivan JK, Andurkar SV. Pharmacology of kratom: an emerging botanical agent with stimulant, analgesic and opioid-like effects. J Am Osteopath Assoc. 2012;112(12):792–799.
- Gershman K, Timm K, Frank M. Deaths in Colorado attributed to kratom. N Engl J Med. 2019;380(1):97–98.
- Kuehn B. Kratom-related deaths. J Am Med Assoc. 2019;321(20):1966.
- Le D, Goggin MM, Janis GC. Analysis of mitragynine and metabolites in human urine for detecting the use of the psychoactive plant kratom. J Anal Toxicol. 2012;36(9):616–625.
- Overbeek DL, Abraham J, Munzer BW. Kratom (mitragynine) ingestion requiring naloxone reversal. Clin Pract Cases Emerg Med. 2019;3(1):24–26.
- Buresh M. Treatment of kratom dependence with buprenorphine-naloxone maintenance. J Addict Med.2018;12(6):481–483.
- Khazaeli A, Jerry JM, Vazirian M. Treatment of kratom withdrawal and addiction with buprenorphine. J Addict Med. 2018;12(6):493–495.
- Smid MC, Charles JE, Gordon AJ, Wright TE. Use of kratom, an opioid-like traditional herb, in pregnancy. Obstet Gynecol. 2018;132(4):926–928.
- Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246–2255.
- U.S. Food and Drug Administration. FDA issues warnings to companies selling illegal, unapproved kratom drug products marketed for opioid cessation, pain treatment and other medical uses. https://www.fda.gov/news-events/press-announcements/fda-issues-warnings-companies-selling-illegal-unapproved-kratom-drug-products-marketed-opioid. Accessed July 19, 2019.
- Post S, Spiller HA, Chounthirath T, Smith GA. Kratom exposures reported to United States poison control centers: 2011–2017. Clin Toxicol (Phila). 2019;57(10):847–854.
- U.S. Food and Drug Administration. FDA and kratom. https://www.fda.gov/news-events/public-health-focus/fda-and-kratom. Accessed May 10, 2019.
- Drug Enforcement Administration US. Drugs of abuse: a DEA resource guide. https://www.dea.gov/sites/default/files/sites/getsmartaboutdrugs.com/files/publications/DoA_2017Ed_Updated_6.16.17.pdf#page=84. Accessed May 10, 2019.
- Throckmorton DC, Gottlieb S, Woodcock J. The FDA and the next wave of drug abuse – proactive pharmacovigilance. N Engl J Med. 2018;379(3):205–207.
- Matson SC, Hobson G, Abdel-Rasoul M, Bonny AE. A retrospective study of retention of opioid-dependent adolescents and young adults in an outpatient buprenorphine/naloxone clinic. J Addict Med. 2014;8(3):176–182.
- Olsen EO, O’Donnell J, Mattson CL, Schier JG, Wilson N. Notes from the field: unintentional drug overdose deaths with kratom detected – 27 states, July 2016–December 2017. Mmwr Morb Mortal Wkly Rep. 2019;68(14):326–327.
- Smith KE, Bunting AM, Walker R, Hall MT, Grundmann O, Castillo O. Non-prescribed buprenorphine use mediates the relationship between heroin use and kratom use among a sample of polysubstance users. J Psychoactive Drugs. 2019;1–12. [epub ahead of print].
- Likhitsathian S, Jiraporncharoen W, Aramrattana A, et al. Polydrug use among kratom users: findings from the 2011 Thailand National Household Survey. J Subst Use. 2018;23(4):384–389.
- National Institutes of Health. What complementary and integrative approaches do Americans use? Key findings from the 2012 National Health Interview Survey. https://nccih.nih.gov/research/statistics/NHIS/2012/key-findings. Accessed May 10, 2019.
- Barry AR. Patients’ perceptions and use of natural health products. Can Pharm J (Ott). 2018;151(4):254–262.
- Bent S. Herbal medicine in the United States: review of efficacy, safety, and regulation – grand rounds at University of California, San Francisco Medical Center. J Gen Intern Med. 2008;23(6):854–859.
- Foley H, Steel A, Cramer H, Wardle J, Adams J. Disclosure of complementary medicine use to medical providers: a systematic review and meta-analysis. Sci Rep. 2019;9(1):1573.